Members Only ContentUpdate Magazine July/August 2015

Posted on August 2015 by FDLI

What’s in a Name? Quantifying the Economic Value of Label Information    by Anthony J. Anscombe....................................................................... 6 more

Members Only ContentUpdate Magazine May/June 2015

Posted on July 2015 by FDLI

Table of Contents  (Coming soon)read more

Members Only ContentUpdate Magazine March/April 2015

Posted on March 2015 by FDLI

Featured Food Labeling Consultations and Modernization in Canada By Martha A. Healey  HIPAA and MOBILE HEALTH APPS: What developers need to know about app user privacy By Cindy J. more

Members Only ContentUpdate Magazine January / February 2015

Posted on January 2015 by FDLI

Table of Contents Featured Risky Business – On the Trial of Tainted Dietary Supplements by Jason Humbert  Between Two Evolving Regulatory Systems: Importing US-Made Foods into more

Members Only ContentUpdate Magazine November/December 2014

Posted on November 2014 by FDLI

read more

Members Only ContentSelf-Enforcement of Regulatory Compliance through a Culture of Credibility

Posted on November 2013 by By Joshua Axelrod, Esq., M.B.A.

At the 2013 Food and Drug Law Institute’s Advertising and Promotion Conference in September, 2013, Mary Riordan from the Office of Counsel to the Inspector General, Department of Health and more

Members Only ContentAttack on Multiple Fronts in Nutraceutical Marketing: The threat of FTC, FDA and Consumer Class Actions

Posted on November 2013 by By Kim M. Schmid, Jenny Young, Katherine Fillmore

Nutraceutical products recently have been the subject of a multitude of class-action lawsuits questioning their marketing, efficacy, and safety.  The often hyperbolic health and nutritional more

Members Only ContentUp to Their Old Devices? Why Differences in Drug and Device Promotion Standards Matter From An Enforcement Perspective

Posted on September 2013 by by John T. Bentivoglio, Jennifer L. Bragg and Maya P. Florence

While pharmaceutical manufacturers have been the most common target of government investigations for violations of advertising and promotion rules, prosecutors and other government enforcement more

China represents a huge potential opportunity for the pharmaceutical industry in both commercial and research and development spaces. In a recent survey, one of the key themes that emerged was more

Members Only ContentConsumer Behavior and FDA Regulation: An FDLI Dialogue

Posted on September 2013 by By Jennifer Kane, Esq, Manager, Tobacco/Drugs Portfolio; Editor

On July 24, nearly 40 participants convened in-person at the D.C. offices of Latham & Watkins LLP and via teleconference for a cross-cutting FDLI Dialogue program focused on consumer behavior more